Cannabis Use, Effect And Potential Therapy For Alzheimer’s, MS and Parkinson’s

“The illegal status and wide-spread use of cannabis made basic and clinical cannabis research difficult in the past decades; on the other hand, it has stimulated efforts to identify the psychoactive constituents of cannabis. As a consequence, the endocannabinoid system was discovered, which was shown to be involved in most physiological systems — the nervous, the cardiovascular, the reproductive, the immune system, to mention a few.

One of the main roles of endocannabinoids is neuroprotection, but over the last decade they have been found to affect a long list of processes, from anxiety, depression, cancer development, vasodilatation to bone formation and even pregnancy.

Cannabinoids and endocannabinoids are supposed to represent a medicinal treasure trove which waits to be discovered…

The endocannabinoid system acts as a guardian against various attacks on the mammalian body.

Conclusion

The above described research concerning the endocannabinoid-system is of importance in both basic science and in therapeutics:

  • The discovery of the cannabis plant active constituent has helped advance our understanding of cannabis use and its effects.
  • The discovery of the endocannabinoids has been of central importance in establishing the existence of a new biochemical system and its physiological roles — in particular in neuroprotection.
  • These discoveries have opened the door for the development of novel types of drugs, such as THC for the treatment of nausea and for enhancing appetite in cachectic patients.
  • The endocannabinoid system is involved in the protective reaction of the mammalian body to a long list of neurological diseases such as multiple sclerosis, Alzheimer’s and Parkinson’s disease which raises hope for novel therapeutic opportunities for these diseases.”

More: http://www.sciencedaily.com/releases/2007/10/071014163644.htm

Smoking Pot Eases Tremors in Parkinson’s

“Smoking cannabis appeared to reduce tremor and pain and improve sleep among Parkinson’s disease patients, researchers from Israel reported here.

Overall, patients’ scores on the standard Unified Parkinson’s Disease Rating Scale (UPDRS) averaged 33 before they smoked cannabis in the laboratory and averaged 24 after 30 minutes (P<0.01), Ruth Djaldetti, MD, of Tel Aviv University Israel, reported at her poster presentation at the International Congress on Parkinson’s Disease and Movement Disorders.

“We not only saw improvement in tremor in these patients, but also in rigidity and in bradykinesia,” Djaldetti told MedPage Today. “I would recommend use of marijuana to my patients as a last resort if nothing else was working for them or if they had pain.””

http://www.medpagetoday.com/meetingcoverage/mds/39933

Poly-ε-caprolactone microspheres as a drug delivery system for cannabinoid administration: development, characterization and in vitro evaluation of their antitumoral efficacy.

“Cannabinoids show promise for the treatment of various medical conditions such as emesis, anorexia, pain, cancer, multiple sclerosis, Parkinson’s disease and glaucoma.

The objective of the present work was to assess the feasibility of developing cannabinoid loaded poly-ε-caprolactone (PCL) microparticles prepared by the oil-in-water emulsion-solvent evaporation technique as a suitable dosage form for their administration.

In vitro cell viability studies demonstrated the antitumoral activity of CBD released from microparticles. After 4 and 7 days of incubation, CBD in microspheres significantly inhibited the growth of MDA-MB-231 cells by 60% as compared to the 50% attained with free drug.

The results suggest that PCL microparticles could be an alternative delivery system for long-term cannabinoid administration, showing potential therapeutic advantages over free drug.”

http://www.ncbi.nlm.nih.gov/pubmed/22580111

Cannabis by product helps reduce effects of Parkinson disease medication

“Researchers from Brazil’s prestigious University of Sao Paulo have discovered that marihuana contains substances which can help ease the collateral effects of medicines prescribed to patients suffering from Parkinson disease.”

Brazilian researchers have tested the positive effects of canabiodiol 

“Six patients with Parkinson were given during a whole month small doses of “canabiodiol” one of the 400 substances in marihuana, following which encouraging results were confirmed according to scientists from the Riberao Preto Medicine School from the SP University.

“Patients with Parkinson developed improvements in their sleeping alterations, in their psychotic symptoms and could even reduce their trembling” said psychiatrist Jose Alexander Crippa, Neuro-sciences Department professor.

The paper on the discovery was published last November and next year an additional paper with test results on the anxiolytic effects of “canabiodiol” in patients with obsession and compulsion disorders will be released.

A group of voluntary patients with obsessive and compulsive conducts were medicated with the substance 70 minutes before facing situations that forced them into anxiety fits, and “improvements were evident”.”

http://en.mercopress.com/2009/12/30/cannabis-by-product-helps-reduce-effects-of-parkinson-disease-medication

Study: Cannabis may prevent brain damage – FOX

“Marijuana continues to be a paradox as it makes its way from illicit drug to wonder medicine being used to treat a number of symptoms and disorders more safely than traditional pharmaceuticals.”

  • 110712_fr_marijuana2_640.jpg
     

“In the latest news, cannabis, which has been associated with long-term cognitive deficits in chronic users, is now being tested as a treatment to preserve brain function after traumatic injury.

…some reports have shown that cannabis has neuroprotective effects. Studies have suggested that it has protective effects in neurodegenerative diseases like multiple sclerosis, Alzheimer’s, Huntington’s and Parkinson’s diseases.”

More: http://www.foxnews.com/health/2013/06/06/study-cannabis-may-prevent-brain-damage/

Read more: http://www.foxnews.com/health/2013/06/06/study-cannabis-may-prevent-brain-damage/#ixzz2VXJJw9yc

The endocannabinoid system and its therapeutic exploitation.

Image result for Nat Rev Drug Discov.

“The term ‘endocannabinoid’ – originally coined in the mid-1990s after the discovery of membrane receptors for the psychoactive principle in Cannabis, Delta9-tetrahydrocannabinol and their endogenous ligands – now indicates a whole signalling system that comprises cannabinoid receptors, endogenous ligands and enzymes for ligand biosynthesis and inactivation. This system seems to be involved in an ever-increasing number of pathological conditions. With novel products already being aimed at the pharmaceutical market little more than a decade since the discovery of cannabinoid receptors, the endocannabinoid system seems to hold even more promise for the future development of therapeutic drugs. We explore the conditions under which the potential of targeting the endocannabinoid system might be realized in the years to come.”  http://www.ncbi.nlm.nih.gov/pubmed/15340387

http://www.nature.com/nrd/journal/v3/n9/full/nrd1495.html

Cannabinoids.

“Since the discovery of an endogenous cannabinoid system, research into the pharmacology and therapeutic potential of cannabinoids has steadily increased. Two subtypes of G-protein coupled cannabinoid receptors, CB(1) and CB(1), have been cloned and several putative endogenous ligands (endocannabinoids) have been detected during the past 15 years. The main endocannabinoids are arachidonoyl ethanolamide (anandamide) and 2-arachidonoyl glycerol (2-AG), derivatives of arachidonic acid, that are produced “on demand” by cleavage of membrane lipid precursors.

 Besides phytocannabinoids of the cannabis plant, modulators of the cannabinoid system comprise synthetic agonists and antagonists at the CB receptors and inhibitors of endocannabinoid degradation. Cannabinoid receptors are distributed in the central nervous system and many peripheral tissues, including immune system, reproductive and gastrointestinal tracts, sympathetic ganglia, endocrine glands, arteries, lung and heart. There is evidence for some non-receptor dependent mechanisms of cannabinoids and for endocannabinoid effects mediated by vanilloid receptors.

Properties of CB receptor agonists that are of therapeutic interest include analgesia, muscle relaxation, immunosuppression, anti-inflammation, antiallergic effects, improvement of mood, stimulation of appetite, antiemesis, lowering of intraocular pressure, bronchodilation, neuroprotection and antineoplastic effects. The current main focus of clinical research is their efficacy in chronic pain and neurological disorders. CB receptor antagonists are under investigation for medical use in obesity and nicotine addiction. Additional potential was proposed for the treatment of alcohol and heroine dependency, schizophrenia, conditions with lowered blood pressure, Parkinson’s disease and memory impairment in Alzheimer’s disease.”

http://www.ncbi.nlm.nih.gov/pubmed/16266285

Cannabis could provide relief for Parkinson’s pain

Woman smokes a marijuana cigarette [illustrative]

“As many as eight out of every 10 of those with Parkinson’s disease suffer from inexplicable pains that until now have been left untreated because they were thought to be an inevitable part of the progressive and eventually fatal neurological disease. Parkinson’s, a brain disorder that leads to tremors and difficulty with walking, coordination and movement, usually develops after age 50 and is one of the most common nervous system disorders of the elderly.But new research at the Rabin Medical Center- Beilinson Campus has found that genetic factors explain such Parkinson’s pain, and that the new understanding will make unique treatments possible. Eight genes known to be involved in pain were examined in 237 Parkinson’s patients, according to a research paper published recently in the European Journal of Pain, and the observed variations were connected to functions of cannabis-like substances (cannabinoids) in the brain.

Research project head Prof. Ruth Djaldetti, a senior physician in the neurology department and head of the movement disorders clinic, said that the results support the treatment of Parkinson’s patients with medical marijuana.

Djaldetti encourages more research into the use of cannabis for pain relief.

There are some 20,000 people with Parkinson’s in Israel, and about 50 percent to 80% of them suffer from this previously unexplained and untreated pain. Djaldetti expects that in the future, gene mapping will make it possible to suit personalized medication to these patients.”

 

Cannabis compound can help cells

“Cannabis has been used recreationally and for medicinal purposes for centuries, yet its 60 plus active components are only partly understood. Now scientists have discovered how a compound in cannabis can help cells to function in our bodies, and aid recovery after a damaging event.

In a paper published in the Journal of Neuroscience, the researchers report on their studies into cannabidiol – a naturally occurring molecule found in cannabis.

Also known as CBD, it is not the constituent that gives the high – that compound is called tetrahydrocannabinol or THC – and so may be more acceptable as a drug treatment.

Both compounds are currently used in a pharmaceutical medicine to help patients relieve pain and other symptoms of Multiple Sclerosis.

Now researchers have discovered how CBD actually works within brain cells.

By interacting with mitochondria – which are the power generators of all cells – it can help maintain normal levels of calcium allowing cells to function properly and providing a greater resistance to damage.

Disturbance of calcium levels has long been associated with a number of brain disorders. So the finding could have implications for the development of new treatments for disorders related to malfunctioning mitochondria.

Dr Bettina Platt, from the University’s School of Medical Sciences, said: “Scientists have known for a long time that cannabidiol can help with pain relief but we never really knew how it worked.

“However we have discovered what it actually does at the cellular level.

“We are hoping that our findings can instruct the development of cannabidiol based treatments for disorders related to mitochondrial dysfunction such as Parkinson’s disease or Huntington’s disease.”

More: http://phys.org/news154280470.html

Cannabidiol: a promising drug for neurodegenerative disorders?

“Neurodegenerative diseases represent, nowadays, one of the main causes of death in the industrialized country. They are characterized by a loss of neurons in particular regions of the nervous system. It is believed that this nerve cell loss underlies the subsequent decline in cognitive and motor function that patients experience in these diseases. A range of mutant genes and environmental toxins have been implicated in the cause of neurodegenerative disorders but the mechanism remains largely unknown. At present, inflammation, a common denominator among the diverse list of neurodegenerative diseases, has been implicated as a critical mechanism that is responsible for the progressive nature of neurodegeneration.

Since, at present, there are few therapies for the wide range of neurodegenerative diseases, scientists are still in search of new therapeutic approaches to the problem. An early contribution of neuroprotective and antiinflammatory strategies for these disorders seems particularly desirable because isolated treatments cannot be effective.

 In this contest, marijuana derivatives have attracted special interest, although these compounds have always raised several practical and ethical problems for their potential abuse. Nevertheless, among Cannabis compounds, cannabidiol (CBD), which lacks any unwanted psychotropic effect, may represent a very promising agent with the highest prospect for therapeutic use.”

http://www.ncbi.nlm.nih.gov/pubmed/19228180